Abbott Laboratories Total Liabilities and Share Holders Equity 2010-2025 | ABT
Abbott Laboratories total liabilities and share holders equity from 2010 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- Abbott Laboratories total liabilities and share holders equity for the quarter ending March 31, 2025 was $81.448B, a 12.39% increase year-over-year.
- Abbott Laboratories total liabilities and share holders equity for 2024 was $81.414B, a 11.2% increase from 2023.
- Abbott Laboratories total liabilities and share holders equity for 2023 was $73.214B, a 1.64% decline from 2022.
- Abbott Laboratories total liabilities and share holders equity for 2022 was $74.438B, a 1.01% decline from 2021.
| Abbott Laboratories Annual Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2024 | $81,414 |
| 2023 | $73,214 |
| 2022 | $74,438 |
| 2021 | $75,196 |
| 2020 | $72,548 |
| 2019 | $67,887 |
| 2018 | $67,173 |
| 2017 | $76,250 |
| 2016 | $52,666 |
| 2015 | $41,247 |
| 2014 | $41,207 |
| 2013 | $42,953 |
| 2012 | $67,235 |
| 2011 | $60,277 |
| 2010 | $60,574 |
| 2009 | $52,582 |
| Abbott Laboratories Quarterly Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2025-03-31 | $81,448 |
| 2024-12-31 | $81,414 |
| 2024-09-30 | $74,356 |
| 2024-06-30 | $73,017 |
| 2024-03-31 | $72,467 |
| 2023-12-31 | $73,214 |
| 2023-09-30 | $72,090 |
| 2023-06-30 | $73,354 |
| 2023-03-31 | $73,794 |
| 2022-12-31 | $74,438 |
| 2022-09-30 | $72,801 |
| 2022-06-30 | $74,202 |
| 2022-03-31 | $74,007 |
| 2021-12-31 | $75,196 |
| 2021-09-30 | $73,795 |
| 2021-06-30 | $73,269 |
| 2021-03-31 | $72,785 |
| 2020-12-31 | $72,548 |
| 2020-09-30 | $69,043 |
| 2020-06-30 | $68,776 |
| 2020-03-31 | $66,777 |
| 2019-12-31 | $67,887 |
| 2019-09-30 | $68,539 |
| 2019-06-30 | $68,427 |
| 2019-03-31 | $67,610 |
| 2018-12-31 | $67,173 |
| 2018-09-30 | $71,637 |
| 2018-06-30 | $68,415 |
| 2018-03-31 | $70,908 |
| 2017-12-31 | $76,250 |
| 2017-09-30 | $72,248 |
| 2017-06-30 | $71,151 |
| 2017-03-31 | $70,887 |
| 2016-12-31 | $52,666 |
| 2016-09-30 | $39,497 |
| 2016-06-30 | $39,831 |
| 2016-03-31 | $39,637 |
| 2015-12-31 | $41,247 |
| 2015-09-30 | $41,725 |
| 2015-06-30 | $44,125 |
| 2015-03-31 | $43,095 |
| 2014-12-31 | $41,207 |
| 2014-09-30 | $42,514 |
| 2014-06-30 | $41,475 |
| 2014-03-31 | $41,662 |
| 2013-12-31 | $42,953 |
| 2013-09-30 | $44,132 |
| 2013-06-30 | $42,903 |
| 2013-03-31 | $42,687 |
| 2012-12-31 | $67,235 |
| 2012-09-30 | $63,258 |
| 2012-06-30 | $61,860 |
| 2012-03-31 | $62,416 |
| 2011-12-31 | $60,277 |
| 2011-09-30 | $59,628 |
| 2011-06-30 | $62,004 |
| 2011-03-31 | $61,651 |
| 2010-12-31 | $60,574 |
| 2010-09-30 | $57,374 |
| 2010-06-30 | $53,381 |
| 2010-03-31 | $53,359 |
| 2009-12-31 | $52,582 |
| 2009-09-30 | $49,847 |
| 2009-06-30 | $47,630 |
| 2009-03-31 | $45,438 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $231.085B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||